Danny Hsu Shares The ”I-WISh” Study by Nichola Cooper on ITP
Danny Hsu, President of THANZ, reposted from ITP Australia and New Zealand on LinkedIn:
”Burden of disease in ITP patients is more significant than we think!
Thanks to the I-WISh study by Nichola Cooper, an excellent insight into what ITP patients go through.”
Quoting ITP Australia and New Zealand‘s post:
”Fatigue in ITP: A symptom that demands attention.
The original I‑WISh study highlighted a critical gap: while patients consistently report fatigue as one of the most disruptive aspects of Immune Thrombocytopenia (ITP), it is often under‑recognised in clinical practice.
“Fatigue has impacted my work, relationships, and daily routine.”
Now, I‑WISh 2.0 results are being finalised — with Australia included — offering fresh insights into patient and physician perspectives worldwide.
For healthcare professionals, this is a call to action: fatigue is not secondary.
It is central to the patient experience and must be addressed with empathy and integrated care strategies.
Explore the findings.”
Stay updated on all scientific advances with Hemostasis Today.
-
May 21, 2026, 10:26Tagreed Alkaltham: The Controlled Flow Behind Modern Apheresis Therapy and Donation
-
May 21, 2026, 09:24Ryan A. Metcalf: Turning Complex Transfusion Data Into Clear Clinical Insights
-
May 21, 2026, 08:58Anu Thomas: The Critical Role of TTI Screening in Safe Blood Transfusion
-
May 21, 2026, 08:07Follow the WHA Discussion on Bleeding Disorders Live – WFH
-
May 21, 2026, 07:23EAHAD Highlights the Power of Clinical Trials in Haemophilia
-
May 21, 2026, 07:10Chai Phua: 1st Publicly Funded Hemgenix Treatment for Hemophilia B in Canada Marks Historic Gene Therapy Milestone
-
May 21, 2026, 07:10Satyam Arora: Improving Thalassemia Outcomes Through Evidence-Based Practice
-
May 21, 2026, 06:55Hayley Evans: Scaling PBM Quality Improvement Through Automated TXA Tracking
-
May 21, 2026, 06:54Ashkan Shoamanesh: FDA Grants Asundexian A Priority Review for Secondary Stroke Prevention